Keros Therapeutics, Inc. Operating Lease Cost
Keros Therapeutics, Inc. (KROS) reported Operating Lease Cost of $4.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-04
- Keros Therapeutics, Inc. operating lease, cost for the quarter ending 2024-12-31 was $1.06M, a 50.71% increase year-over-year.
- Keros Therapeutics, Inc. operating lease, cost for the quarter ending 2023-12-31 was $702.00K, a 80.46% increase year-over-year.
- Keros Therapeutics, Inc. operating lease, cost for the quarter ending 2022-12-31 was $389.00K, a 71.37% increase year-over-year.
- Keros Therapeutics, Inc. operating lease, cost for the quarter ending 2021-12-31 was $227.00K, a 90.76% increase year-over-year.
- Keros Therapeutics, Inc. operating lease, cost for fiscal 2025 was $4.23M, a 20.16% increase from fiscal 2024.
- Keros Therapeutics, Inc. operating lease, cost for fiscal 2024 was $3.52M, a 19.36% increase from fiscal 2023.
- Keros Therapeutics, Inc. operating lease, cost for fiscal 2023 was $2.95M, a 170.89% increase from fiscal 2022.
- Keros Therapeutics, Inc. operating lease, cost for fiscal 2022 was $1.09M, a 85.52% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $4.23M 10-K · filed 2026-03-04 | ||||
| 2024-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $3.52M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $2.46M 10-Q · filed 2024-11-06 | ||||
| 2023-12-31 | $702.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.95M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $2.25M 10-Q · filed 2024-11-06 | $2.20M 10-Q · filed 2023-11-06 | |||
| 2022-12-31 | $389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.09M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $347.00K derived: sum of 2 quarters · filed 2024-02-28 | $587.00K 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $120.00K 10-Q · filed 2021-11-04 | $360.00K 10-Q · filed 2021-11-04 | |||
| 2020-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $235.00K derived: sum of 2 quarters · filed 2022-03-09 | $468.00K 10-K · filed 2022-03-09 | ||
| 2020-09-30 | $116.00K 10-Q · filed 2021-11-04 | $349.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $278.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |